Pulmonary delivery of siRNA against acute lung injury/acute respiratory distress syndrome
对尖锐的肺 injury/acute 的 siRNA 的肺的交货呼吸悲痛症候群作者机构:Department of PharmaceuticsSchool of PharmacyChina Pharmaceutical UniversityNanjing 211198China Department of Industrial PharmacyFaculty of PharmacyAlexandria UniversityAlexandria 21521Egypt Shanghai Skin Disease HospitalTongji University School of MedicineShanghai 200443China
出 版 物:《Acta Pharmaceutica Sinica B》 (药学学报(英文版))
年 卷 期:2022年第12卷第2期
页 面:600-620页
核心收录:
学科分类:100702[医学-药剂学] 1007[医学-药学(可授医学、理学学位)] 1006[医学-中西医结合] 100602[医学-中西医结合临床] 10[医学]
基 金:supported by the National Natural Science Foundation of China(Nos.81872823,and 82073782) the Shanghai Science and Technology Committee(No.19430741500) the Key Laboratory of Modern Chinese Medicine Preparation of Ministry of Education of Jiangxi University of Traditional Chinese Medicine(TCM-201905,China)
主 题:Pulmonary administration Drug delivery Nanoparticles siRNA Cellular uptake Endosomal escape Inflammatory diseases ALI/ARDS
摘 要:The use of small interfering RNAs(si RNAs)has been under investigation for the treatment of several unmet medical needs,including acute lung injury/acute respiratory distress syndrome(ALI/ARDS)wherein si RNA may be implemented to modify the expression of pro-inflammatory cytokines and chemokines at the m RNA *** properties such as clear anatomy,accessibility,and relatively low enzyme activity make the lung a good target for local si RNA ***,the translation of si RNA is restricted by the inefficient delivery of si RNA therapeutics to the target cells due to the properties of naked si ***,this review will focus on the various delivery systems that can be used and the different barriers that need to be surmounted for the development of stable inhalable si RNA formulations for human use before si RNA therapeutics for ALI/ARDS become available in the clinic.